Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000470

EU PAS number

EUPAS1000000470

Study ID

1000000470

Official title and acronym

Real-world Comparative Effectiveness of Anti-EGFRs with Doublet Chemotherapy Versus Doublet Chemotherapy with or without Bevacizumab in Firstline Among RAS/RAF Wild-type, non-dMMR/MSI High mCRC Patients with Left-sided Primary Tumors in the Flatiron Health CRC Enhanced Datamart (20240215)

DARWIN EU® study

No

Study countries

United States

Study status

Ongoing
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable